- Ascentage Pharma Group reported an initial statement of beneficial ownership by director Changqing Ye dated 03/18/2026.
- Ye reported direct ownership of options for 56,550 ordinary shares with an exercise price of USD 8.14.
- He also reported direct ownership of 66,550 restricted stock units tied to ordinary shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-031660), on March 19, 2026, and is solely responsible for the information contained therein.